Astrazeneca Pharma India Share Price Slips to Fresh 52-Week Low at Rs 6,218: Here’s Why
- September 29, 2026
- Posted by: Harsh Piplani
- Category: News
Astrazeneca Pharma India Share Price fell to Rs 6,270, down 0.28% from the previous close of Rs 6,287.50, and touched a fresh 52-week low of Rs 6,217.50 in today’s trade. The company’s market capitalisation stood at Rs 15,718.75 crore, placing this move in a large-market-value context for Astrazeneca Pharma India Ltd. (ASTRAZEN). The supplied data confirms the one-year low event and shows the stock opened at Rs 6,308.25, moved between Rs 6,217.50 and Rs 6,335.50, and ended below the prior close. The data supports the price event, but it does not establish a company-specific catalyst, so the focus remains on verified price action, valuation and sector context in this Astrazeneca Pharma India Share Price update from Univest.
The fresh 52-week low makes Astrazeneca Pharma India Stock News relevant for investors tracking Astrazeneca Pharma India Share Price Today, especially because the current quote sits close to the day’s low and below the previous close. In Univest’s reading of the supplied figures, the event is about the recorded price outcome rather than an inferred reason. That is why the next step is to examine the day’s move, valuation multiples, earnings profile and comparison with the Healthcare sector and Pharmaceuticals & Drugs peers.
Astrazeneca Pharma India Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 6,270 |
| Previous Close | Rs 6,287.5 |
| Today's Move | Rs -17.5 (-0.28%) |
| Open | Rs 6,308.25 |
| High | Rs 6,335.5 |
| Low | Rs 6,217.5 |
| Turnover | Rs 0.04 crore |
| Market Capitalisation | Rs 15,718.75 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,270. versus the previous close of Rs 6,287.5, a fall of 0.28%. The stock opened at Rs 6,308.25, reached Rs 6,335.5, touched Rs 6,217.5.
Astrazeneca Pharma India Share Price Today finished at Rs 6,270 after opening at Rs 6,308.25, touching an intraday high of Rs 6,335.50 and low of Rs 6,217.50. The stock is down Rs 17.50, or 0.28%, from the previous close of Rs 6,287.50, and the day’s low matched the fresh 52-week low of Rs 6,217.50. Turnover stood at Rs 0.04 crore. The market capitalisation was Rs 15,718.75 crore, which keeps the move in view against the company’s overall size. In plain terms, the Astrazeneca Pharma India Share Price event today shows a new yearly low being set, with the closing quote still above the low but below the prior session’s close. For readers following Astrazeneca Pharma India Share Price Live, the verified numbers point to a weak session on price terms alone, and the next lens is the stock’s financial context.
Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 15,718.75 crore |
| P/E Ratio | 92.67x |
| P/B Ratio | 17.38x |
| ROE | 23.02% |
| ROCE | 31.24% |
| EPS | Rs 67.85 |
| Book Value Per Share | Rs 361.68 |
| Dividend Yield | 0.57% |
Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 92.67x, P/B 17.38x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.
Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 15718.75 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 92.67x, P/B at 17.38x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.57%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.53x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 92.67x |
| Benchmark Median P/E | 32.53x |
| Benchmark Average P/E | 48.74x |
| Benchmark P/E Range | 3.46x to 707.31x |
| Company P/B Ratio | 17.38x |
| Benchmark Median P/B | 2.87x |
| Company ROE | 23.02% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 31.24% |
| Benchmark Median ROCE | 13.46% |
| Company Market Capitalisation | Rs 15,718.75 crore |
| Benchmark Median Market Cap | Rs 782.41 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 92.67x, which is above the benchmark median of 32.53x, a difference of +184.88%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.7%, a difference of +96.75%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.46%, a difference of +132.1%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Marksans Pharma Ltd. | MARKSANS | 15,267.09 | 29.08 | 4.73 | 15.31 | 21.1 |
| Concord Biotech Ltd. | CONCORDBIO | 15,213.29 | 52.96 | 7.03 | 13.54 | 18.04 |
| Natco Pharma Ltd. | NATCOPHARM | 15,046.12 | 12.96 | 1.59 | 16.3 | 17.16 |
| Glenmark Life Sciences Ltd. | ALIVUS | 16,510.3 | 27.38 | 4.74 | 18.41 | 24.61 |
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,975.19 | 24.21 | 2.87 | 12.35 | 11.74 |
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 92.67x compared with the displayed peer median of 27.38x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 15.31% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 18.04%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 15,718.75 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Astrazeneca Pharma India
- Astrazeneca Pharma India Share Price hit a fresh 52-week low of Rs 6,217.50 today.
- The stock closed at Rs 6,270, which is down 0.28% from the previous close of Rs 6,287.50.
- Market capitalisation stood at Rs 15,718.75 crore in the latest session.
- P/E is 92.67 and P/B is 17.38, both above the same-industry median in the supplied benchmark.
- ROE is 23.02%, ROCE is 31.24%, and EPS is Rs 67.85 in the supplied fundamentals.
About Astrazeneca Pharma India
Astrazeneca Pharma India Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied company profile data identifies the business within this classification and supports a stock-level read through industry benchmarks, peer comparisons and core financial indicators. For Astrazeneca Pharma India Share Price, the company’s identity is best understood through the verified market-cap, earnings, return and valuation numbers that accompany the stock event.
Track Astrazeneca Pharma India Share Price on Univest
Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Track Astrazeneca Pharma India Share Price on Univest for live price updates, share price today coverage, shareholding pattern insights, key fundamental ratios, market cap, 52-week levels and market views. Univest brings Astrazeneca Pharma India Share News, Astrazeneca Pharma India Latest News and stock analysis together in one place for easier monitoring.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Astrazeneca Pharma India Share Price hit a fresh 52-week low?
Ans. The supplied data confirms that Astrazeneca Pharma India Share Price touched Rs 6,217.50, its fresh 52-week low. The record does not establish a company-specific catalyst, so the event should be read as verified price action.
What is Astrazeneca Pharma India Share Price today?
Ans. Astrazeneca Pharma India Share Price closed at Rs 6,270, down 0.28% from the previous close of Rs 6,287.50. The day’s range was Rs 6,217.50 to Rs 6,335.50, with turnover at Rs 0.04 crore.
What does Astrazeneca Pharma India Share Price say about valuation?
Ans. Astrazeneca Pharma India Share Price sits alongside a P/E of 92.67 and a P/B of 17.38. Those figures are above the supplied same-industry medians, which gives the stock a premium valuation context.
How strong are Astrazeneca Pharma India fundamentals?
Ans. The supplied fundamentals show ROE of 23.02%, ROCE of 31.24%, EPS of Rs 67.85 and book value of Rs 361.68. Revenue and profit figures from recent quarters also provide additional context.
How does Astrazeneca Pharma India compare with peers?
Ans. Astrazeneca Pharma India Share Price is associated with a market cap of Rs 15,718.75 crore, near Marksans Pharma and Concord Biotech. Its P/E and return ratios are higher than several listed peers in the supplied set.
What sector and industry does Astrazeneca Pharma India belong to?
Ans. Astrazeneca Pharma India operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. That places Astrazeneca Pharma India Share Price within a broad benchmark set of 198 same-industry companies and 285 same-sector companies.
